SAN ANTONIO – A subset of patients with early-stage triple-negative breast cancer may benefit from treatment with adjuvant capecitabine, according to a subgroup analysis of a Phase III study presented at the San Antonio Breast Cancer Symposium here this week, and researchers are applying genomic analysis to characterize them in more detail.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.